GCP
ELEV

GSA Capital Partners’s Elevation Oncology ELEV Stock Holding History

GSA Capital Partners’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-433,545
Closed -$260K – 1709
2024
Q3 		$260K Buy
+433,545
New +$643K 0.02% 1293

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GSA Capital Partners's ELEV Position: Q4 2024 in Review

GSA Capital Partners sold out of Elevation Oncology (ELEV) in Q4 2024, closing a stake of 433,545 shares — an estimated $260K sold.

GSA Capital Partners first reported a position in ELEV in Q3 2024 and held it in 1 quarter. The position peaked at $260K in Q3 2024. 71 funds tracked by Wall St. Rank hold ELEV as of Q4 2024.

  • GSA Capital Partners reported no remaining Elevation Oncology position as of Q4 2024 after selling out during the quarter.
  • GSA Capital Partners sold 433,545 Elevation Oncology shares in Q4 2024, an estimated $260K.
  • GSA Capital Partners first reported a position in Elevation Oncology in Q3 2024 and held it in 1 quarter.
  • GSA Capital Partners's Elevation Oncology position peaked at $260K in Q3 2024.
  • 71 funds tracked by Wall St. Rank held Elevation Oncology as of Q4 2024.

Based on GSA Capital Partners's 13F filing for Q4 2024, filed 7 Feb 2025.